Friday, October 2, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· February 26, 2026

Top Research Reports for Meta, Netflix & Pfizer

View original at finance.yahoo.com
Top Research Reports for Meta, Netflix & Pfizer Thursday, February 26, 2026 The Zacks Research Daily presents the best research output of our analyst team…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Pfizer expects its recently launched and acquired products and a strong pipeline to help revive top-line growth toward the end of the decade

    80% confidence
  • Flowers Foods fourth quarter total company volume declined 2.2%

    80% confidence
  • Netflix has about two hours of viewing per member per day

    80% confidence
  • Altigen's top five accounts represented 83% of sales

    80% confidence
  • Recommendation improvement drove 20% lift in time spent on Threads

    80% confidence
  • Instagram Reels had a strong fourth-quarter, with watch time up more than 30% year-over-year in the United States

    80% confidence
  • Facebook video time continued to grow double-digits year-over-year in the United States

    80% confidence
  • Meta Platforms now expects to invest significantly more over the next few years in developing more advanced models and the largest AI services in the world

    80% confidence
  • Meta's improved recommendation system is driving up user engagement

    80% confidence
  • 2026 guidance projects revenue growth of 12-14% for Netflix

    80% confidence
  • Monetization of AI services will take considerable time

    80% confidence
  • Netflix has set an ambitious target to double its revenues by 2030 and reach a $1 trillion market capitalization

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com